The field of joint disorders is one of the areas in which Fidia has been active longest.
The result is the development of new molecules and new technology, such as new uses of hyaluronic acid, ever a winning card in the company portfolio.
Forty years of research into hyaluronic acid have placed Fidia at the forefront in technological development, production and economic turnover, not only in Italy but worldwide.
Fidia offers an exciting new approach to the treatment of osteoarthritis, effectively controlling pain and delaying the progress of cartilage damage.
It is now possible to restore traumatic lesions with cartilage grafts using cells taken from the same patient, thanks to a revolutionary, tissue-engineering technique devised by Fidia’s subsidiary, Fidia Advanced Biopolymers.